(TheNewswire)
LONDON, ONTARIO – TheNewswire - April 21, 2021 – Sernova Corp. (TSXV:SVA)(OTC:SEOVF) (FSE/XETRA:PSH ), a leading clinical-stageregenerative medicine therapeutics company, today announced that itwill host a virtual Key Opinion Leader (KOL) event on thyroid disease,current treatment options and the potential of a novel cell therapytreatment approach for postoperative hypothyroidism. The event willtake place on Tuesday April 27 th , 2021, at 1:00 PM ET.
The event will feature a presentation from Dr. SamWiseman, a leading academic thyroid/parathyroid surgeon andinternationally recognized expert in the management of thyroid andparathyroid disease.
"This KOL event will provide the unique opportunity for ourinvestors to learn about thyroid disease, current treatments, andexciting advancements towards a novel cell therapy treatment approachaimed to provide a functional cure for patients suffering frompostoperative hypothyroidism," said Dr. Philip Toleikis,President and CEO of Sernova. "Participants will also be able toenter into a conversation through a Q&A period with Dr. Wiseman, aprominent physician in the management of thyroid disease."
Dr. Wiseman's presentation will be madeavailable on Sernova's website before the call. All questions to Dr.Wiseman, can be submitted to info@sernova.com prior tothe call.
To register and access the Zoom link for this event, please click:
https://zoom.us/webinar/register/2016189463384/WN_LF8impNgRzqpbSMeLdeMww
Following the event, a recording will be available at www.sernova.com .
ABOUT SERNOVA'S HYPOTHYROID PROGRAM
Sernova's immediate approach in treating hypothyroiddisease is to transplant healthy thyroid tissue followingthyroidectomy (removal of the thyroid gland) into the pre-implantedvascularized Cell Pouch to recover the normal function of the thyroidgland. In collaboration with Dr. Wiseman, preclinical proof of conceptwork conducted under a grant from the British Columbia TransplantFoundation is contributing to advancing Sernova's plans to conductclinical assessment of the Cell Pouch with transplanted thyroid tissuein patients suffering from hypothyroid disease. Sernova's treatmentgoal is to preserve thyroid function and improve patient quality oflife relative to current treatments.
Thyroidectomy is commonly performed for cancerdiagnosis or treatment and for treatment of benign (non-cancerous)disease that includes goiter and hyperthyroidism. It is estimated thatabout 150,000 thyroidectomies are performed in the US yearly, and themajority of individuals undergoing a thyroid operation are diagnosedwith benign diseases after their procedure. Patients with Grave'sdisease and thyroid nodules undergoing total thyroidectomy, and manypatients undergoing partial thyroidectomy require life-long thyroidhormone replacement.
Post-surgical thyroid hormone replacement therapy, ifmonitored carefully, can be effective; however, patients often sufferfrom deleterious side-effects including weight gain, depression,headaches, and cardiovascular disease, with resultant negative impacton quality of life, and significant costs to the healthcare system. Webelieve Sernova's development of new therapeutic strategies toovercome hypothyroidism has the potential to meet an important unmetmedical need.
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutic technologiesusing a medical device and immune protected therapeutic cells (i.e.human donor cells, corrected human cells and stem cell-derived cells)to improve the treatment and quality of life of people with chronicmetabolic diseases such as insulin-dependent diabetes, blood disordersincluding hemophilia, and other diseases treated through replacementof proteins or hormones missing or in short supply within the body.For more information, please visit www.sernova.com .
FOR FURTHER INFORMATION, PLEASECONTACT:
Dominic Gray
Sernova Corp.
Tel: (519) 858-5126
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-lookingstatements are statements that are not historical facts and aregenerally, but not always, identified by the words"expects", "plans", "anticipates","believes", "intends", "estimates","projects", "potential" and similar expressions,or that events or conditions "will", "would","may", "could" or "should" occur.Although Sernova believes the expectations expressed in suchforward-looking statements are based on reasonable assumptions, suchstatements are not guarantees of future performance, and actualresults may differ materially from those in forward-lookingstatements. Forward-looking statements are based on the beliefs,estimates, and opinions of Sernova's management on the date suchstatements were made, which include our beliefs about the conduct andoutcome of clinical trials. Sernova expressly disclaims any intentionor obligation to update or revise any forward-looking statementswhether as a result of new information, future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.